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In this study, we investigated the anti-angiogenic eﬀect of the Chinese herbal decoction Danggui Buxue Tang (DBT; Radix Astragali
and Radix Angelicae sinensis in 5 : 1 ratio) in a rat model of liver fibrosis, in order to elucidate its mechanisms of action against liver
fibrosis. Liver fibrosis was induced with CCl4 and high-fat food for 6 weeks, and the rats were treated with oral doses of DBT (6 g
raw herbs/kg/d) and N-Acetyl-L-cysteine (NAC; 0.1 g/kg/d). The results showed that both DBT and NAC attenuated liver fibrosis
and neo-angiogenesis. Furthermore, DBT and NAC improved SOD activity but decreased MDA content and 8-OH-dG in fibrotic
livers, with DBT being more eﬀective than NAC. DBT decreased the expression of VEGF, Ang1 and TGF-β1 and their signaling
mediators, whereas NAC had no eﬀect on VEGF and VEGFR2 expression. Both DBT and NAC reduced HIF-1α gene and protein
expression in fibrotic livers, with DBT being more eﬀective. These data clearly demonstrate that the anti-fibrotic properties of DBT
are related to its ability to inhibit angiogenesis and its anti-angiogenic mechanisms are associated with improving oxidative stress,
regulating the expression and signaling of angiogenic factors, and especially modulating HIF-1α in fibrotic livers.
1. Introduction
Angiogenesis is a hypoxia-driven and growth factor-de-
pendent process that leads to the formation of neovas-
culature from preexisting blood vessels. Experimental and
clinical studies have unequivocally shown that pathological
angiogenesis, irrespective of etiology, plays a key role in the
fibrogenic progression of chronic liver diseases [1–3], and the
inhibition of pathological angiogenesis in liver not only can
stop liver cancer development, but also regress or reverse liver
fibrosis [4, 5].
Danggui Buxue Tang (DBT), an ancient traditional Chi-
nese herbal formula composed of Huangqi (Radix Astragali)
and Danggui (Radix Angelica sinensis) with a weight ratio of
5 : 1, has wide pharmacological actions, including regulation
of immune functions and protection against liver injuries
[6]. Although there are no reports concerning the eﬀect
of DBT on liver cirrhosis, several studies have reported
antifibrotic eﬀects for its components. For example, the
combination of Astragali and Angelicae sinensis significantly
inhibited the progression of renal fibrosis. This treatment
led to a decrease in histologic damage, type III and IV
collagen expression, fibronectin, and laminin in a rat model
of chronic puromycin-induced nephrosis [7]. Astragali sig-
nificantly attenuated liver tissue collagen and hydroxyproline
(Hyp) content in a rat model of liver fibrosis induced by
albumin immune complex [8]. In a rat model of pulmonary
fibrosis induced by intratracheal instillation of bleomycin,
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Table 1: Antibodies used in the study.
Antibody Isotype Suppliers Cat. no. Dilution
Collagen type I Mouse IgG1 Sigma C2456 1 : 400
α-SMA Rabbit polyclonal IgG Abcam ab5694 1 : 400
vWF Rabbit polyclonal IgG Abcam ab6994 1 : 200
PECAM-1 Goat polyclonal IgG Santa Cruz sc-1506 1 : 200
HIF-1α Rabbit monoclonal IgG EPIT MICS #2015-1 1 : 200
VEGF Rabbit polyclonal IgG Abcam ab46154 1 : 400
VEGFR2 Rabbit polyclonal IgG Abcam ab39638 1 : 500
Angiopoietin 1 Rabbit polyclonal IgG Abcam ab95230 1 : 200
Tie-2 Rabbit polyclonal IgG Abcam ab71712 1 : 250
TGF-β1 Mouse IgG1 R&D systems MAB240 1 : 500
TGFβ-R1 Rabbit polyclonal IgG Cell signal technology #3712 1 : 1000
TGFβ-R2 Mouse IgG2a Santa Cruz sc-17792 1 : 200
ERK Mouse IgG2b Santa Cruz sc-1647 1 : 200
p-ERK Mouse IgG2a Santa Cruz sc-7383 1 : 200
Angelica sinensis ameliorated fibrosis by inhibiting throm-
boxane B2 level and transforming growth factor-β1 (TGF-
β1) expression [9].
Our previous study found that DBT was able to ame-
liorate liver fibrosis induced by carbon tetrachloride (CCl4)
in rats, with the best results seen with a 5 : 1 ratio of Radix
Astragali and Radix Angelicae sinensis [10]. In a subsequent
study, we showed that this protective eﬀect of DBT was
associated with the prevention of lipid peroxidation and
the inhibition of matrix metalloproteinases 2/9 (MMP 2/9)
activities in fibrotic livers [11].
In the present study, we observed the eﬀects of DBT
on angiogenesis in fibrotic livers, with the antioxidant N-
Acetyl-L-cysteine (NAC) as a positive control drug. To test
the hypothesis that the antifibrotic properties of DBT are
related to its ability to inhibit angiogenesis, we also analyzed
its eﬀects on oxidative stress injury, expression of VEGF,
TGF-β1, and Ang1, expression of VEGF-R2, TGFβ-R1/2 and
Tie2 receptors, and ERK phosphorylation, in particular HIF-
1α expression in the fibrotic liver. Collectively, our data
demonstrate that the anti-angiogenic mechanisms of DBT in
fibrotic livers are associated with improving oxidative stress,
regulating angiogenic factors expression and signaling, and
especially modulating the gene and protein expression of
HIF-1α.
2. Materials and Methods
2.1. Reagents. CCl4, olive oil and N-Acetyl-L-cysteine (NAC)
were purchased from Shanghai National Chemicals Co.,
Ltd. (Shanghai, China). Bovine serum albumin (BSA) was
purchased from Sino-American Biotechnology Co. (Henan,
China). The primary antibodies used in this study are
listed in Table 1. Nitrocellulose membrane (Hybond-C, opti-
mized for protein transfer) was purchased from Amersham
Biosciences UK, Ltd. (Buckinghamshire, UK). Horseradish
peroxidase-labeled goat anti-mouse antibody and goat anti-
rabbit antibody were obtained from Santa Cruz Biotech-
nology (California, USA). Cy3-labeled goat anti-rabbit IgG
(H+L), Cy3-labeled donkey anti-goat IgG (H+L), and
2-(4-Amidinophenyl)-6-indolecarbamidine dihydrochloride
(DAPI) were provided by the Beyotime Institute of Biotech-
nology (Jiangsu, China). The BCA Protein Assay Kit and the
SuperSignal West Pico Chemiluminescent Substrate (ECL)
were obtained from Pierce Chemical Company (Rockford,
USA). TRIzol was obtained from Invitrogen (California,
USA). The First-Strand cDNA Synthesis Kit (K1622) was
purchased from Fermentas (St. Leon-Roth, Germany). The
SYBR Green Real Time PCR Kit (DRR041A) was from
TakaRa Biotechnology Co., Ltd (Dalian, China). Superoxide
dismutase (SOD), malondialdehyde (MDA), and 8-hydroxy-
deoxyguanosine (8-OH-dG) were obtained from Nanjing
Jiancheng Bioengineering Institute (Nanjing, China).
2.2. Preparation of Danggui Buxue Decoction. DBT consists
of Radix Astragali and Radix Angelica sinensis in a 5 : 1 ratio.
The herbs originated from Gansu province, China. Slices
of the herbs were purchased from Shanghai Huayu Chinese
Herbs Co., Ltd. The medicinal herbs were extracted twice.
Radix Astragali (1000 g) and Radix Angelica sinensis (200 g)
were first boiled together in 6x volume of water for 1 h,
and then the residue from first extraction was boiled in
8x volume of water for 1.5 h. Finally, the filtered solutions
were combined and concentrated into the resulting aqueous
extracts containing 0.9 g/mL raw herbs. The quantitative
analyses of active compounds were verified by Professor Li.
Yang (Table 2).
2.3. Animal Models of Liver Fibrosis and Drug Treatment.
Fifty-four male Wistar rats (SCXK [Shanghai] 2007-005)
were obtained from the Shanghai Laboratory Animal Center
of the Chinese Academy of Sciences. All animal protocols
were carried out in accordance with ethical guidelines, and
animals had free access to chow and water throughout the
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Table 2: The amounts of six compounds in DBT.
Compound
DBT (Radix Astragali : Radix
Angelica sinensis = 5 : 1)
Astragaloside IV 61.63± 2.06
Calycosin 2.29± 0.08
Calycosin-7-O-β-D-glucoside 2.20± 0.03
Formononetin 0.68± 0.00
Formononetin-7-O-β-D-
glucoside
1.12± 0.07
Ferulic acid 0.98± 0.02
Values are expressed in 10−2 mg/g of raw herbs and are in X ± sd, n = 3.
experiments. Liver fibrosis was induced by subcutaneous
injection of CCl4 and the administration of food with a high
lipid content and lower protein content [12]. Briefly, the rats
received a single injection of 100% CCl4 at 5mL/kg and then
3mL/kg of 40% CCl4 dissolved in olive oil twice every week
for 6 weeks. These rats were pair-fed with a high lipid and low
protein diet containing 79.5% corn flour, 20% lard, and 0.5%
cholesterol for the first 2 weeks, then with pure corn flour
feeds for the following 4 weeks. Rats in the normal group
(n = 8) did not receive CCl4 treatment and were fed a normal
diet.
The model rats were randomly divided into three groups:
model (n = 12), DBT (n = 12), and NAC (n = 12). The
rats in the DBT group received intragastric administrations
of DBT at 6 g (raw herbs)/kg/d. Rats in the NAC group
received intragastric administrations of NAC at 0.1 g/kg/d.
Both drug treatment duration is 6 weeks, which means from
the beginning of intoxication to the end of experiment, and
both dosages are equivalent to 10 times the clinical dosage for
a 60 kg adult. Rats in the normal and model groups received
the same volume (10mL/kg) of normal saline.
2.4. Pathological Examination. Liver specimens were pre-
served in 4% formaldehyde and dehydrated in a graded
alcohol series. The specimens were then embedded in
paraﬃn blocks, cut into 4 μm thick sections and placed on
glass slides. Sections were then stained with Sirius red.
2.5. Hepatic Hyp Content Examination. Hepatic Hyp content
was measured with a modified version of the method devel-
oped by Jamall et al. [13]. Briefly, 100mg of liver samples
were homogenized and hydrolyzed in 12 M HCl at 110◦C
for 18 h. After filtration of the hydrolysate through filtration
paper, chloramine T was added to a final concentration of
2.5mM for 10 min at room temperature. The mixture was
then treated with 25% (w/v) p-dimethylaminobenzaldehyde
and 27.3% (v/v) perchloric acid in isopropanol (Ehrlich’s
reagent solution) and incubated at 50◦C for 90 min. After
cooling to room temperature, the samples were examined at
558 nm against a reagent blank that contained the complete
system without tissue. The concentration of Hyp in each
sample was determined from a standard curve, which was
generated from a serial of known quantities of Hyp from
0.2 to 1.6 μg Hyp (Peptide Co. Japan). The Hyp content is
expressed as μg/g of liver wet weight.
2.6. Immunohistochemistry. 4 μm thick sections were used
for immunohistochemical examinations. After deparaf-
finization and dehydration, microwave antigen retrieval was
performed for 5min prior to peroxidase quenching with 3%
H2O2 in PBS for 15min. Consequently, the sections were
preblocked with 5% bovine serum albumin for 30min. Slides
were incubated at 4◦C with primary antibodies (Table 1)
at 37◦C for 70min and then with biotinylated secondary
antibodies for 45min. They were then developed with DAB
for 3min and finally counterstained with hematoxylin. For
the negative controls, the primary antibody was replaced
with PBS.
2.7. Immunofluorescence. Frozen liver tissue slices (7 μm
thick) were fixed with cold acetone for 10 min and dried in
air for 30 min. The slices were rinsed with PBS for 3 × 5min
and blocked with 0.2% BSA for 1 h at 37◦C before being
incubated with the specific primary antibodies (Table 1).
To visualize the primary antibodies, the slices were stained
with cy3-labeled secondary antibodies for 1 h at 37◦C.
After nuclear staining with DAPI (1 : 1000; Beyotime) for
1 min, the slices were observed using immunofluorescence
microscopy (OLYMPUS ZX70). Negative control staining
was performed using PBS instead of the primary antibody.
Microvessel density was determined in the tissue as the
mean number of labeled vessel sections in 5 successive high-
magnification fields (×400) with IPP software. The results
are expressed as the means ± SD.
2.8. Western Blotting Analysis. Liver tissues were homog-
enized in RIPA lysis buﬀer (150 mM NaCl, 1% Nonidet
P-40, 0.1% SDS, 50mM Tris-HCl pH 7.4, 1mM EDTA,
1mM PMSF, and 1×Roche complete mini protease inhibitor
cocktail). The supernatants were collected by centrifugation
at 10,000×g at 4◦C for 15min. Protein concentration was
determined using a BCA Protein Assay Kit. Equal amounts
of protein were separated by 10% SDS gel electrophoresis
(SDS-PAGE) under denaturing and nonreducing conditions
and then transferred to a nitrocellulose membrane. The
membrane was blocked with 5% nonfat milk in TBST at
room temperature for 1 h and then incubated with primary
antibody (Table 1) at 4◦C overnight. After washing in
TBST, the blots were incubated with a horseradish-coupled
secondary antibody. The signals were visualized using the
enhancement system (ECL).
2.9. Fluorescence Western Blot. The fluorescence western blot
protocol is the same as the general western blot protocol until
the membrane transformation step. The membranes were
blocked in blocking buﬀer (Odyssey, LI-COR, USA) for 1 h
at room temperature followed by incubation with primary
antibodies (Table 1) at 4◦C overnight. After washing in PBS,
the blots were incubated with the second antibody (Donkey
anti-Rabbit IRDye 680 antibody; 1 : 10000; Odyssey) for
1 h at room temperature. After washing, the densities of
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Table 3: Primers used for real-time PCR.
Gene Primer sequences Gene bank accession no. Length (bp)
HIF1α
5′-CCAGATTCAAGATCAGCCAGCA-3′
NM 024359 100
5′-GCTGTCCACATCAAAGCAGTACTCA-3′
β-actin
5′-TGA CGA GGC CCA GAG CAA GA-3′
DQ237887 331
5′-ATG GGC ACA GTG TGG GTG AC-3′
immunoreactive bands were quantified and corrected for
GAPDH signal with Li-Cor Odyssey 2.1 software (LI-COR,
USA).
2.10. RNA Extraction and Quantitative Real-Time PCR.
Total RNA was isolated from the liver tissues with TRIzol
according to the manufacturer’s instructions. RNA purity
was determined spectrophotometrically, and its integrity was
verified by agarose gel electrophoresis. First-Strand cDNA
was synthesized by reverse transcribing 4 μg of total RNA in
a final reaction volume of 20 μL using a First-Strand cDNA
Synthesis Kit according to the manufacturer’s instructions.
Primer oligonucleotide sequences specific for real-time PCR
are shown in Table 3 and were designed and synthesized by
Sangon Biotech Inc. (Shanghai, China). The PCR mixtures
contained 1 μL cDNA, 10 μL SYBR Premix Ex Tq 2X, and
0.25 μmol/L forward and reverse primers in a final volume of
20 μL. Triplicate reactions were performed with a Rcorbett
6.0 system (Rotor-Gene 3000), starting with a polymerase
activation step for 10 s at 95◦C, followed by 40 cycles
of 5 s at 95◦C and 20 s at 60◦C. Fluorescence data were
acquired after each cycle. The absence of primer dimers and
unspecific products was verified after every run by melting
curve analysis (72 to 95◦C) and agarose gel electrophoresis.
2.11. Hepatic Oxidative Injury Examination. SOD, MDA and
8-OH-dG levels in the liver homogenates were quantified
using commercially available kits according to the manu-
facturer’s instructions (Nanjing Jiancheng Co. Ltd.). Results
were normalized to the total amount of protein measured by
bicinchoninic acid (BCA).
2.12. Statistical Analysis. Statistical tests were performed
using SPSS software version 12.0. Diﬀerences between two
groups were analyzed by the SNK-q’ test. P values lower than
0.05 were considered statistically significant.
3. Results
3.1. DBT andNACAmeliorated Liver Fibrosis Induced by CCl4.
The model rats had increased collagen deposition in the
liver, which formed fibrous septa and cirrhotic nodules or
pseudolobules. The doses of DBT and NAC used in this study
were calculated according to their usage in patients with
liver cirrhosis. Figures 1(a) and 1(b) show that DBT- and
NAC-treated rats had much less liver collagen accumulation
compared to the model control. This was confirmed with
Hyp content as a specific marker for collagen synthesis.
Compared to normal rats, Hyp content was increased
Table 4: Eﬀect of DBT on hepatic HIF-1α mRNA expression in
CCl4-induced fibrosis in rats (X ± sd).
Group n HIF-1α /β-actin mRNA
Normal 3 0.98± 0.03
Model 3 3.32± 0.46##
DBT 3 0.49± 0.04∗∗∧∧
NAC 3 0.86± 0.05∗∗
##P < 0.01 versus normal group, ∗∗P < 0.01 versus model group, ∧∧P <
0.01 versus NAC group.
significantly in model rats and significantly decreased by
DBT and NAC treatment (P < 0.01; Figure 1(c)).
3.2. Eﬀect of DBT and NAC on Hepatic Stellate Cell (HSC)
Activation. α-SMA is a marker of HSC activation. We
measured the expression of α-SMA by immunohistochem-
ical staining and western blot analysis. CCl4 treatment
caused a significant increase in the expression of α-SMA
positive HSCs around damaged hepatocytes and fibrotic
bands compared to the normal group. In DBT- and NAC-
treated animals, the number of α-SMA-positive HSCs was
significantly reduced. Western blot analysis revealed that
the α-SMA expression in model rats was almost 5 times
higher than that in normal rats. Treatment with DBT and
NAC resulted in significant reductions. In addition, there
was a significant diﬀerence between the DBT and NAC
group (P < 0.01; Figures 2(a), 2(b) and 2(c)); DBT was more
eﬀective.
3.3. Eﬀect of DBT and NAC on Tissue Angiogenesis.
Immunofluorescence for von Willebrand factor (vWF) and
platelet/endothelial cell adhesion molecule-1 (PECAM-1,
also referred to as CD31) was performed to analyzemicroves-
sel growth. In normal livers, vWF is expressed in the
great vessels of the portal tract and central veins but not
along sinusoids, and CD31 is rarely expressed. In CCl4-
treated livers, we observed vWF/CD31-positive microvessels
located in fibrotic areas surrounding larger vessels, as well
as in emerging fibrotic septa. As illustrated in Figure 3(c),
DBT and NAC reduced the number of vWF/CD31-positive
microvessels, which were also concentrated in fibrotic areas.
DBT was more eﬀective than NAC in reducing vWF expres-
sion (P < 0.01).
3.4. Eﬀect of DBT and NAC on Hypoxia Inducible Factor
(HIF)-1α. Real-time PCR analysis showed that the expres-
sion of HIF-1α mRNA in the model livers was 3 times
higher than in the normal group (Table 4). DBT and NAC
Evidence-Based Complementary and Alternative Medicine 5
Table 5: Eﬀect of DBT and NAC on hepatic SOD activity and MDA and 8-OH-dG contents in CCl4-induced fibrosis (X ± sd).
Group n MDA (μmol/g) SOD (NU/g) 8-OHDG (ng/mL)
Normal 8 457.9± 140.6 42.9± 8.7 1.6± 0.6
Model 10 1054.5± 255.0## 24.7± 4.1## 2.8± 0.8##
DBT 12 642.8± 277.2∗∗ 37.7± 7.2∗∗∧ 2.0± 0.4∗
NAC 12 617.9± 344.5∗∗ 30.3± 15.8∗ 1.7± 0.9∗∗
##P < 0.01 versus normal group, ∗∗P < 0.01 versus model group, ∧∧P < 0.01 versus NAC group. Two rats in model group died in 6 weeks of modeling.
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Figure 1: Eﬀects of DBT and NAC on liver fibrosis induced by CCl4. (a) Sirius red staining of collagen deposition in liver fibrosis. CCl4
induced an increase in liver collagen. DBT and NAC decreased the collagen deposition in the fibrotic liver tissue. (b) Immunohistochemical
staining of type I collagen protein expression in liver tissue (DAB). The model group had much stronger and more extensive positive staining
among fibrotic septa compared with the normal group. DBT and NAC significantly decreased the amount of positive staining. (c) Liver Hyp
content was determined using Jamall’s method. The Hyp content was increased significantly in the model group compared with the normal
group. DBT and NAC treatment significantly decreased liver Hyp content. ##P < 0.01 versus normal group, ∗∗P < 0.01 versus model group.
significantly decreased this expression (Table 4). This was
confirmed with HIF-1α immunostaining (Figure 4). In the
livers of normal animals, HIF-1α immunolabeling was rarely
detected. In the fibrotic livers, HIF-1α immunolabeling was
highly expressed, especially in zone III of the acinus. DBT
and NAC decreased HIF-1α expression in the fibrotic livers
(P < 0.05). Consistent with the immunohistochemistry find-
ings, western blot analysis showed that HIF-1α expression
was significantly increased in the fibrotic livers (P < 0.01,
versusnormal group). DBT and NAC decreased HIF-1α
expression (P < 0.01), with a significant diﬀerence between
the two treatment groups (P < 0.01).
3.5. Eﬀects of DBT and NAC on Hepatic Oxidative Injury.
CCl4 intoxication significantly increased hepatic contents of
MDA and 8-OH-dG, and decreased hepatic SOD activity
(Table 5) (P < 0.01, versus normal group). DBT and NAC
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Figure 2: Eﬀect of DBT and NAC on α-SMA protein expression in CCl4-induced fibrotic liver tissue in rats. (a) Immunohistochemical
staining, DAB × 200. Normal liver tissue had little positive staining. Tissue from the model group had much stronger and more extensive
positive staining among fibrotic septa and in the sinusoidal area. DBT and NAC significantly decreased the amount of positive staining. (b) A
representative western blot. Consistent with the immunohistochemistry findings, the semi-quantitative value of the α-SMA western blot was
significantly increased in fibrotic livers. Compared to the model control group, DBT significantly decreased α-SMA expression, and the eﬀect
of DBT was more pronounced than that of NAC. (c) A histogram plot showing the densitometric analysis corresponding to the mean ± SD
of three independent experiments. ##P < 0.01 versus normal group, ∗∗P < 0.01 versus model group, ∧∧P < 0.01 versus NAC group.
reduced hepatic MDA and 8-OH-dG contents, increased the
SOD activity (P < 0.05). In addition, DBT has better eﬀect
than NAC on increasing SOD activity in fibrotic liver.
3.6. Eﬀects of DBT and NAC on Expression of VEGF, Ang1
and TGF-β1 and Their Signaling Mediators. Western blot
analysis (Figure 5) showed that the expressions of pro-
angiogenic growth factors such as VEGF, TGF-β1, and
Ang1 elevated in fibrotic livers (P < 0.01, versus normal
group), and their respective receptors—VEGF-R2, TGFβR-
1/2 and Tie2 also increased. ERK is common down-stream
signaling mediator for VEGF, TGF-β1, and so forth, the
result showed that phosphorylation of ERK-1/2 increased
remarkably, although total ERK1 has no change. DBT,
but not NAC, significantly decreased VEGF and VEGF-R2
protein expression (P < 0.01), and there was a significant
diﬀerence in VEGF expression between DBT- and NAC-
treated groups. (P < 0.01). Both DBT and NAC down-
regulated TGFβ-R1/2 and Tie2 expression and ERK-1/2
phosphorylation in fibrotic liver (P < 0.05), compared to the
model control.
4. Discussion
The liver fibrosis, caused by many etiologies such as viruses,
toxins, alcohol and cholestasis and so forth, is an essential
pathological process in chronic liver diseases, and lead
into cirrhosis which is end stage of chronic liver diseases.
Therefore, it is very important to find an approach for curing
or regressing liver fibrosis. Angiogenesis is the main process
of new vessel formation, and accompanies liver fibrosis [2].
Recently a increasing body of evidences has shown that
angiogenesis play a crucial role in liver fibrogenesis [14], and
the inhibition of angiogenesis with multitargeted receptor
tyrosine kinase inhibitors sunitinib or sorafenib could regress
or reverse liver fibrosis in animals [15, 16]. Angiogenesis, a
hypoxia-driven and growth factor-dependent process, also
plays a key role in the development of cirrhosis [1, 2, 5, 17–
20]. Since the conventional therapies are not desirable for
curing liver fibrosis, the manipulation of angiogenesis could
be a promising approach for treatment of liver fibrosis.
According to traditional Chinese medicine (TCM) the-
ory, liver fibrosis is caused by a dual deficiency of Qi-yin
and blood stasis [21]. DBT has good function of nourishing
Qi (energy flow) and Xue (blood), as well as resolving
Yuxue (blood stasis), and has been used traditionally to
treat menopausal disorders [6]. In our previous study, we
found that DBT could ameliorate CCl4-induced liver fibrosis
in rats [11]. In this study, we found that in normal livers,
vWF and CD31, two markers of angiogenesis, are expressed
few and limited to the large vessels of the periportal region
and could not be found along sinusoids. However, their
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Figure 3: Eﬀect of DBT and NAC on vWF and CD31 expression in CCl4-induced fibrotic liver tissue in rats, (a, b) Microvessel density in
diﬀerent groups. Immunofluorescence for vWF and CD31 was performed to analyze microvessel growth. In normal livers, the expression
of vWF was limited to large vessels located in the periportal zone with no expression along the sinusoids, and no CD31 expression was
observed. In CCl4-treated livers, increased vWF/CD31-positive microvessels were seen primarily in fibrotic areas. DBT- and NAC-treated
livers showed reduced amounts of vWF/CD31-positive microvessels, which were also concentrated in fibrotic areas. A significant diﬀerence
in vWF expression was seen between DBT- and NAC-treated groups. (c) A bar graph representation of microvessel density reported as the
mean number of labeled vessel sections in 5 successive high-magnification fields (×400). The results are expressed as mean ± SD for three
separate experiments. ##P < 0.01 versus normal group, ∗∗P < 0.01 versus model group, ∧∧P < 0.01 versus NAC group.
expression increased remarkably in fibrous septa and along
sinusoids in fibrotic livers, which means that rich neovessels
formed in fibrotic livers. While DBT and NAC treatment
could decrease the expression of vWF and CD31 proteins,
indicating that DBT and NAC can inhibit liver angiogenesis,
which may be one of the action mechanisms of DBT and
NAC antifibrotic property. It is reported recently that the
thiol antioxidant NAC had eﬀect against liver fibrosis [22]
and decreased tumor angiogenesis and tumorigenesis [23];
our current study confirmed NAC’s eﬀect on liver fibrosis
and find its new action on fibrotic liver angiogenesis.
Angiogenesis is a dynamic, hypoxia-stimulated and
growth factor-dependent process. A recent document has
identified that there are number of common cellular
and molecular mechanisms between angiogenesis and liver
fibrosis, with a specific emphasis on the crucial role of
hypoxic conditions, angiogenic factors and HSC activation.
The hypoxia play a central role in angiogenesis through
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Figure 4: Eﬀect of DBT and NAC on HIF-1α protein expression in CCl4-induced fibrotic liver tissue in rats. (a) Immunohistochemistry
(DAB× 200). In normal livers, HIF-1α immunolabeling was rarely detected. In fibrotic livers, HIF-1α immunolabeling was highly expressed,
especially in zone III of the acinus. DBT and NAC decreased HIF-1α expression in the fibrotic livers. (b) A representative western blot.
Consistent with the immunohistochemistry findings, the semiquantitative value of the HIF-1α western blot was significantly increased in
fibrotic livers. Compared to the model rats, DBT and NAC significantly decreased the expression of HIF-1α, with DBT being more eﬀective
than NAC. (c) A histogram showing HIF-1α protein semiquantified by densitometric analysis and expressed as the mean±SD for three
separate experiments. ##P < 0.01 versus normal group, ∗∗P < 0.01 versus model group, ∧∧P < 0.01 versus NAC group.
inducing HIF-1α [24]. HIF-1α is a heterodimeric DNA
binding complex, it serve as a key regulator of the molecular
hypoxia response and mediates a wide range of physiological
and pathological processes. In the study, although we did
not check hepatic hypoxia by assaying pO2 etc., HIF-1α, a
hypoxia-driven factor, was mainly expressed in perivenous
region (hepatic zone III area) where O2 concentration is
lowest in liver and susceptible to be damaged. And fibrotic
liver had much higher levels of gene and protein expression
of HIF-1α, while DBT and NAC decrease this pathological
elevated HIF-1α levels, in particular HIF-1α expression in
perivenous region, these suggested that DBT and NAC
action against liver angiogenesis was associated with down-
regulation of HIF-1α, which at least partly own to improving
hypoxia condition.
However, HIF-1α upregulation could be hypoxia-
independent, as elicited by growth factors, oncogenes, and
oxidative stress and injury and so forth. The oxidative stress
could cause lipid peroxidative products such as MDA and
8-OH-dG, leading to liver injury and angiogenesis [25],
which can be regulated by endogenous antioxidant enzymes
such as SOD and thioredoxin [26]. Recent studies have
shown that antioxidants such as NAC can inhibit tumor
angiogenesis [27]. In the study, we found DBT and NAC
both improve SOD activity but decrease contents of MDA
and 8-OH-dG in fibrotic liver, indicating that DBT and NAC
inhibition of HIF-1α and angiogenesis is related to their
eﬀect on oxidative stress and injury. VEGF, TGF-β1, and
Ang1 are potent angiogenic and fibrogenic factors, which
may induce angiogenesis directly through their signaling
pathway or indirectly by inducing HIF-1α which in turn
promote its target genes including VEGF expression. VEGF,
TGF-β1 and Ang1 stimulate vascular development and
stabilization through signaling mediators, including their
receptors—VEGF-R1/2 and TGFβ-R1/2, Tie2 and mitogen-
activated protein kinase (MAPK) cascade [28, 29]. In the
present study, DBT not only inhibited the expression of
growth factors including VEGF, TGF-β1, and Ang1, but
also downregulated their receptors expression and ERK
phosphorylation which is common cytoplasmic mediator,
indicating that the inhibition of VEGF, TGF-β1 and Ang1
and their signaling is another important mechanism for DBT
action on HIF-1α, and against angiogenesis and liver fibrosis.
In addition, MMP-2/9 play potent role in initiation of
angiogenesis and activation of HSC, while activated HSCs
synthesizing Ang 1 and VEGF contribute to both fibrogenesis
and neovascularization [20]. In a previous study, we showed
that the protective eﬀect of DBT was associated with the
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Figure 5: Eﬀect of DBT and NAC on VEGF, Angiopoietin 1 and TGF-β1 signaling in CCl4-induced fibrotic liver tissue in rats. (a) The
expression of VEGF and VEGFR2 protein was detected by western blot. Compared to the normal group, the expression of VEGF and
VEGFR2 was significantly increased in fibrotic livers. DBT, but not NAC, significantly decreased VEGF and VEGFR2 expression, and there
was a significant diﬀerence in VEGF expression between DBT- and NAC-treated groups. (c) The expression of the Angiopoietin 1 and Tie 2
protein was detected by western blot. Compared to the normal group, the expression of Ang1 and Tie 2 was increased in fibrotic livers. DBT
andNAC decreased Ang1 and Tie 2 expression. (e) The expression of the TGF-β1/TGFβ-R protein was detected by western blot. Compared to
the normal group, TGFβ1/TGFβ-R protein expression was significantly increased in fibrotic livers. DBT and NAC significantly decreased the
expression of TGFβ1/TGFβ-R. (g) The expression of ERK and p-ERK protein was detected by western blot. Although there was no significant
diﬀerence in ERK protein expression among the four groups, p-ERK protein expression was significantly increased in fibrotic livers. DBT
and NAC significantly decreased p-ERK protein expression, and there was a significant diﬀerence between DBT- and NAC-treated groups.
(b, d, f, h) Histograms of VEGF/VEGFR2, Ang1/Tie 2, TGFβ1/TGFβ-R, and ERK/p-ERK expression. The proteins were semi-quantified by
densitometric analysis and expressed as the mean ± SD for three separate experiments. ##P < 0.01 versus normal group, ∗∗P < 0.01 versus
model group, ∧∧P < 0.01 versus NAC group.
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inhibition of MMP 2/9 activities in fibrotic livers [11].
And the current experiment reconfirmed that DBT and
NAC inhibited HSC activation in vivo, which suggest that
inhibition of MMP-2/9 and HSC activation is the third
mechanism of DBT action mechanism against angiogenesis
in fibrotic liver.
It is interesting to note that DBT can stimulate the
production of erythropoietin, a specific hematopoietic
growth factor, mediated by increasing the mRNA and
protein expression of HIF-1α as well as the activation of
Raf/MEK/ERK signaling pathway in cultured cells [30].
While these data appear to contradict our findings, these
data collectively illustrate the potential of DBT and other
herbal formulations in modulating cellular pathophysiology
to achieve the desirable clinical outcome.
In summary, we found that DBT inhibits angiogenesis
in CCl4-induced liver fibrosis in rats in the current study,
which is closely related to DBT anti-fibrotic property; and
that DBT reduces the expression of HIF-1α, VEGF, TGF-β1,
and Ang1, decreases the receptors expression of VEGF-R2,
TGFβ-R1/2 and Tie2, downregulates ERK phosphorylation,
and improves hepatic oxidative injury in fibrotic liver; these
eﬀects contribute to the overall action mechanisms of DBT
against liver angiogenesis and fibrosis.
Glossary
DBT: Danggui Buxue Tang
NAC: N-Acetyl-L-cysteine
CCl4: Carbon tetrachloride
α-SMA: Alpha-smooth muscle actin
HIF-1α: Hypoxia inducible factor-1α
vWF: von Willebrand factor
PECAM-1: Platelet/endothelial cell adhesion
molecule-1, also referred to as CD31
VEGF: Vascular endothelial growth factor
VEGF-R2: Vascular endothelial growth factor receptor
2, also referred to as KDR
TGF-β1: Transforming growth factor-β1
TGFβ-R: Transforming growth factor-β1 receptor
p-ERK: Phospho-extracellular signal-regulated
kinase
BSA: Bovine serum albumin
ECM: Extracellular matrix
CLDs: Chronic liver diseases
DAPI: 2-(4-Amidinophenyl)-6-indolecarbamidine
dihydrochloride
Hyp: Hydroxyproline
HSC: Hepatic stellate cell
MMPs: Metalloproteinases
SOD: Superoxide dismutase
MDA: Malondialdehyde
8-0H-dG: 8-hydroxy-deoxyguanosine
Ang1: Angiopoietin 1
Tie2: Tyrosine kinase with immunoglobulin G-like
and endothelial growth factor-like domain 2.
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